Related references
Note: Only part of the references are listed.CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials
Kenneth F. Schulz et al.
ANNALS OF INTERNAL MEDICINE (2010)
MENU LABELING: KNOWLEDGE FOR A HEALTHIER AMERICA
Tamara Schulman
HARVARD JOURNAL ON LEGISLATION (2010)
Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?
R. Bilous
DIABETIC MEDICINE (2008)
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study):: a multicentre, randomised, double-blind, controlled trial
Johannes F. E. Mann et al.
LANCET (2008)
Telmisartan, ramipril, or both in patients at high risk for vascular events
Salim Yusuf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes
Hirofumi Makino et al.
DIABETES CARE (2007)
Reduction of microalbuminuria in patients with type 2 diabetes - The Shiga Microalbuminuria Reduction Trial (SMART)
Koubin Tomita et al.
DIABETES CARE (2007)
Olmesartan reducing incidence of endstage renal disease in diabetic nephropathy trial (ORIENT): Rationale and study design
Enyu Imai et al.
HYPERTENSION RESEARCH (2006)
Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine
Sarah E. McDowell et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both
SD Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes - An Asian perspective from the RENAAL study
JCN Chan et al.
DIABETES CARE (2004)
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors:: the CHARM-Added trial
JJV McMurray et al.
LANCET (2003)
Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus - A blood pressure-independent effect
G Viberti et al.
CIRCULATION (2002)
Global and societal implications of the diabetes epidemic
P Zimmet et al.
NATURE (2001)
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
JN Cohn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
BM Brenner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
EJ Lewis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
HH Parving et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and Lisinopril microalbuminuria (CALM) study
CE Mogensen et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
Fibrinogen, other cardiovascular risk factors and diabetes mellitus in Hong Kong: a community with high prevalence of Type 2 diabetes mellitus and impaired glucose tolerance
TH Lam et al.
DIABETIC MEDICINE (2000)
Preserving renal function in adults with hypertension and diabetes: A consensus approach
GL Bakris et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2000)
Share Paper
